Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa
Background Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). Objectives To perform a scoping review of pain me...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2022-12, Vol.187 (6), p.846-854 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 854 |
|---|---|
| container_issue | 6 |
| container_start_page | 846 |
| container_title | British journal of dermatology (1951) |
| container_volume | 187 |
| creator | Hasan, Samar B. Gendra, Riham James, JaBreia Morris, Delyth Orenstein, Lauren A.V. Ingram, John R. |
| description | Background
Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
Objectives
To perform a scoping review of pain measurement in randomized control trials (RCTs) of painful skin conditions (PSCs) and use of the pain numerical rating scale (NRS) and visual analogue scale (VAS) in rheumatoid arthritis RCTs, to inform the efforts of HISTORIC to reach consensus on how to measure pain intensity in HS trials.
Methods
A search was conducted on several publication databases. Inclusion criteria were RCTs with a minimum of 10 participants that measured pain intensity.
Results
Pain NRS and VAS were used in 68% of PSC trials. Respectively, 77% and 87% of PSC and rheumatoid arthritis RCTs did not specify the recall window. The commonest recall window in PSCs when specified was 24 h. In total, 33% of PSC trials assessed maximum pain intensity and 3% average pain intensity, while 87% of rheumatoid arthritis trials did not provide details. Pain data were reported as mean difference by 76% of PSC trials and 75% of rheumatoid arthritis trials. Respectively, 10% and 11% of PSC and rheumatoid arthritis studies reported pain as the percentage of patients reaching a desirable state and only 1% and 2% reported number needed to treat.
Conclusions
While pain NRS and VAS are standard methods to measure pain intensity in PSCs, key details such as the recall window are often omitted and there is no consensus on how to report pain NRS data.
What is already known about this topic?
Pain is the most burdensome symptom experienced by patients with hidradenitis suppurativa and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
What does this study add?
Our review shows substantial variation in how pain numerical rating scale (NRS) and visual analogue scale are utilized in clinical trials. This variation restricts meta‐analysis of pain intensity results.
There is a need for consensus regarding the recall window for pain NRS and maximum vs. average pain, and whether current pain should be measured.
The review looked at the tools used to measure pain in painful skin conditions and how Pain NRS and VAS were used in randomized clinical trials (RCTs) of painful skin conditions and rheumatoid arthritis. The results showed a discrepancy |
| doi_str_mv | 10.1111/bjd.21821 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10087046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2745695663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4441-d60e5d4737783bf2942a4e26b59be7bce83d29d478e5ae3e4e0309fd1979c3963</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEokvhwB9AlrjAIa0_YifmgqB8qxIc4Gw58aTrJbGDnWxVfhK_ktndUkElfLHH8-idd-wpiseMnjBcp-3GnXDWcHanWDGhZMmZEHeLFaW0LqlW4qh4kPOGUiaopPeLIyG14lLJVfHri_WBjGDzkmCEMBMMJ7zrl4Hk7xh0MTg_-xgyscGRtIZltHP0jtg0rxOmMkmYiaP_CW6HzykOAx7n5O2QXxBLchcnHy5Igq2HSzJHrNLHNO4r3a6-9i5ZB2GvnJdpWpKd_dY-LO71qAePrvfj4tu7t1_PPpTnn99_PHt1XnZVVbHSKQrSVbWo60a0PdcVtxVw1UrdQt120AjHNQINSAsCKqCC6t4xXetO4GMdFy8PutPSjuA6tJXsYKbkR5uuTLTe_JsJfm0u4tYwSpuaVjuFZ9cKKf5YIM9m9LmDYbAB4pINrylnaE9pRJ_eQjdxSQH7Q6qSSkulBFLPD1SXYs4J-hs3jJrdCBgcAbMfAWSf_G3_hvzz5wicHoBLP8DV_5XM609vDpK_AUOqwDc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2745695663</pqid></control><display><type>article</type><title>Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Hasan, Samar B. ; Gendra, Riham ; James, JaBreia ; Morris, Delyth ; Orenstein, Lauren A.V. ; Ingram, John R.</creator><creatorcontrib>Hasan, Samar B. ; Gendra, Riham ; James, JaBreia ; Morris, Delyth ; Orenstein, Lauren A.V. ; Ingram, John R.</creatorcontrib><description>Background
Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
Objectives
To perform a scoping review of pain measurement in randomized control trials (RCTs) of painful skin conditions (PSCs) and use of the pain numerical rating scale (NRS) and visual analogue scale (VAS) in rheumatoid arthritis RCTs, to inform the efforts of HISTORIC to reach consensus on how to measure pain intensity in HS trials.
Methods
A search was conducted on several publication databases. Inclusion criteria were RCTs with a minimum of 10 participants that measured pain intensity.
Results
Pain NRS and VAS were used in 68% of PSC trials. Respectively, 77% and 87% of PSC and rheumatoid arthritis RCTs did not specify the recall window. The commonest recall window in PSCs when specified was 24 h. In total, 33% of PSC trials assessed maximum pain intensity and 3% average pain intensity, while 87% of rheumatoid arthritis trials did not provide details. Pain data were reported as mean difference by 76% of PSC trials and 75% of rheumatoid arthritis trials. Respectively, 10% and 11% of PSC and rheumatoid arthritis studies reported pain as the percentage of patients reaching a desirable state and only 1% and 2% reported number needed to treat.
Conclusions
While pain NRS and VAS are standard methods to measure pain intensity in PSCs, key details such as the recall window are often omitted and there is no consensus on how to report pain NRS data.
What is already known about this topic?
Pain is the most burdensome symptom experienced by patients with hidradenitis suppurativa and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
What does this study add?
Our review shows substantial variation in how pain numerical rating scale (NRS) and visual analogue scale are utilized in clinical trials. This variation restricts meta‐analysis of pain intensity results.
There is a need for consensus regarding the recall window for pain NRS and maximum vs. average pain, and whether current pain should be measured.
The review looked at the tools used to measure pain in painful skin conditions and how Pain NRS and VAS were used in randomized clinical trials (RCTs) of painful skin conditions and rheumatoid arthritis. The results showed a discrepancy in how pain NRS/VAS were measured in the trials. In addition, the mean difference was the most common method of reporting pain.
Plain language summary available online</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.21821</identifier><identifier>PMID: 35962565</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Clinical trials ; Collaboration ; Evidence‐Based Dermatology ; Hidradenitis Suppurativa - complications ; Hidradenitis Suppurativa - diagnosis ; Hidradenitis Suppurativa - therapy ; Humans ; Meta-analysis ; Pain ; Pain - diagnosis ; Pain - etiology ; Pain Measurement ; Patients ; Randomized Controlled Trials as Topic ; Rheumatoid arthritis ; Skin diseases ; Systematic Review</subject><ispartof>British journal of dermatology (1951), 2022-12, Vol.187 (6), p.846-854</ispartof><rights>2022 The Authors. published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.</rights><rights>2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4441-d60e5d4737783bf2942a4e26b59be7bce83d29d478e5ae3e4e0309fd1979c3963</citedby><cites>FETCH-LOGICAL-c4441-d60e5d4737783bf2942a4e26b59be7bce83d29d478e5ae3e4e0309fd1979c3963</cites><orcidid>0000-0002-5257-1142 ; 0000-0002-0298-7115 ; 0000-0003-0534-2854 ; 0000-0002-3265-4530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.21821$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.21821$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35962565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasan, Samar B.</creatorcontrib><creatorcontrib>Gendra, Riham</creatorcontrib><creatorcontrib>James, JaBreia</creatorcontrib><creatorcontrib>Morris, Delyth</creatorcontrib><creatorcontrib>Orenstein, Lauren A.V.</creatorcontrib><creatorcontrib>Ingram, John R.</creatorcontrib><title>Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Background
Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
Objectives
To perform a scoping review of pain measurement in randomized control trials (RCTs) of painful skin conditions (PSCs) and use of the pain numerical rating scale (NRS) and visual analogue scale (VAS) in rheumatoid arthritis RCTs, to inform the efforts of HISTORIC to reach consensus on how to measure pain intensity in HS trials.
Methods
A search was conducted on several publication databases. Inclusion criteria were RCTs with a minimum of 10 participants that measured pain intensity.
Results
Pain NRS and VAS were used in 68% of PSC trials. Respectively, 77% and 87% of PSC and rheumatoid arthritis RCTs did not specify the recall window. The commonest recall window in PSCs when specified was 24 h. In total, 33% of PSC trials assessed maximum pain intensity and 3% average pain intensity, while 87% of rheumatoid arthritis trials did not provide details. Pain data were reported as mean difference by 76% of PSC trials and 75% of rheumatoid arthritis trials. Respectively, 10% and 11% of PSC and rheumatoid arthritis studies reported pain as the percentage of patients reaching a desirable state and only 1% and 2% reported number needed to treat.
Conclusions
While pain NRS and VAS are standard methods to measure pain intensity in PSCs, key details such as the recall window are often omitted and there is no consensus on how to report pain NRS data.
What is already known about this topic?
Pain is the most burdensome symptom experienced by patients with hidradenitis suppurativa and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
What does this study add?
Our review shows substantial variation in how pain numerical rating scale (NRS) and visual analogue scale are utilized in clinical trials. This variation restricts meta‐analysis of pain intensity results.
There is a need for consensus regarding the recall window for pain NRS and maximum vs. average pain, and whether current pain should be measured.
The review looked at the tools used to measure pain in painful skin conditions and how Pain NRS and VAS were used in randomized clinical trials (RCTs) of painful skin conditions and rheumatoid arthritis. The results showed a discrepancy in how pain NRS/VAS were measured in the trials. In addition, the mean difference was the most common method of reporting pain.
Plain language summary available online</description><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Clinical trials</subject><subject>Collaboration</subject><subject>Evidence‐Based Dermatology</subject><subject>Hidradenitis Suppurativa - complications</subject><subject>Hidradenitis Suppurativa - diagnosis</subject><subject>Hidradenitis Suppurativa - therapy</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Pain</subject><subject>Pain - diagnosis</subject><subject>Pain - etiology</subject><subject>Pain Measurement</subject><subject>Patients</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rheumatoid arthritis</subject><subject>Skin diseases</subject><subject>Systematic Review</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kk1v1DAQhiMEokvhwB9AlrjAIa0_YifmgqB8qxIc4Gw58aTrJbGDnWxVfhK_ktndUkElfLHH8-idd-wpiseMnjBcp-3GnXDWcHanWDGhZMmZEHeLFaW0LqlW4qh4kPOGUiaopPeLIyG14lLJVfHri_WBjGDzkmCEMBMMJ7zrl4Hk7xh0MTg_-xgyscGRtIZltHP0jtg0rxOmMkmYiaP_CW6HzykOAx7n5O2QXxBLchcnHy5Igq2HSzJHrNLHNO4r3a6-9i5ZB2GvnJdpWpKd_dY-LO71qAePrvfj4tu7t1_PPpTnn99_PHt1XnZVVbHSKQrSVbWo60a0PdcVtxVw1UrdQt120AjHNQINSAsCKqCC6t4xXetO4GMdFy8PutPSjuA6tJXsYKbkR5uuTLTe_JsJfm0u4tYwSpuaVjuFZ9cKKf5YIM9m9LmDYbAB4pINrylnaE9pRJ_eQjdxSQH7Q6qSSkulBFLPD1SXYs4J-hs3jJrdCBgcAbMfAWSf_G3_hvzz5wicHoBLP8DV_5XM609vDpK_AUOqwDc</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Hasan, Samar B.</creator><creator>Gendra, Riham</creator><creator>James, JaBreia</creator><creator>Morris, Delyth</creator><creator>Orenstein, Lauren A.V.</creator><creator>Ingram, John R.</creator><general>Oxford University Press</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5257-1142</orcidid><orcidid>https://orcid.org/0000-0002-0298-7115</orcidid><orcidid>https://orcid.org/0000-0003-0534-2854</orcidid><orcidid>https://orcid.org/0000-0002-3265-4530</orcidid></search><sort><creationdate>202212</creationdate><title>Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa</title><author>Hasan, Samar B. ; Gendra, Riham ; James, JaBreia ; Morris, Delyth ; Orenstein, Lauren A.V. ; Ingram, John R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4441-d60e5d4737783bf2942a4e26b59be7bce83d29d478e5ae3e4e0309fd1979c3963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Clinical trials</topic><topic>Collaboration</topic><topic>Evidence‐Based Dermatology</topic><topic>Hidradenitis Suppurativa - complications</topic><topic>Hidradenitis Suppurativa - diagnosis</topic><topic>Hidradenitis Suppurativa - therapy</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Pain</topic><topic>Pain - diagnosis</topic><topic>Pain - etiology</topic><topic>Pain Measurement</topic><topic>Patients</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rheumatoid arthritis</topic><topic>Skin diseases</topic><topic>Systematic Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasan, Samar B.</creatorcontrib><creatorcontrib>Gendra, Riham</creatorcontrib><creatorcontrib>James, JaBreia</creatorcontrib><creatorcontrib>Morris, Delyth</creatorcontrib><creatorcontrib>Orenstein, Lauren A.V.</creatorcontrib><creatorcontrib>Ingram, John R.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasan, Samar B.</au><au>Gendra, Riham</au><au>James, JaBreia</au><au>Morris, Delyth</au><au>Orenstein, Lauren A.V.</au><au>Ingram, John R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>187</volume><issue>6</issue><spage>846</spage><epage>854</epage><pages>846-854</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><abstract>Background
Pain is the most common and bothersome symptom experienced by people with hidradenitis suppurativa (HS) and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
Objectives
To perform a scoping review of pain measurement in randomized control trials (RCTs) of painful skin conditions (PSCs) and use of the pain numerical rating scale (NRS) and visual analogue scale (VAS) in rheumatoid arthritis RCTs, to inform the efforts of HISTORIC to reach consensus on how to measure pain intensity in HS trials.
Methods
A search was conducted on several publication databases. Inclusion criteria were RCTs with a minimum of 10 participants that measured pain intensity.
Results
Pain NRS and VAS were used in 68% of PSC trials. Respectively, 77% and 87% of PSC and rheumatoid arthritis RCTs did not specify the recall window. The commonest recall window in PSCs when specified was 24 h. In total, 33% of PSC trials assessed maximum pain intensity and 3% average pain intensity, while 87% of rheumatoid arthritis trials did not provide details. Pain data were reported as mean difference by 76% of PSC trials and 75% of rheumatoid arthritis trials. Respectively, 10% and 11% of PSC and rheumatoid arthritis studies reported pain as the percentage of patients reaching a desirable state and only 1% and 2% reported number needed to treat.
Conclusions
While pain NRS and VAS are standard methods to measure pain intensity in PSCs, key details such as the recall window are often omitted and there is no consensus on how to report pain NRS data.
What is already known about this topic?
Pain is the most burdensome symptom experienced by patients with hidradenitis suppurativa and has been prioritized as an outcome domain by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).
What does this study add?
Our review shows substantial variation in how pain numerical rating scale (NRS) and visual analogue scale are utilized in clinical trials. This variation restricts meta‐analysis of pain intensity results.
There is a need for consensus regarding the recall window for pain NRS and maximum vs. average pain, and whether current pain should be measured.
The review looked at the tools used to measure pain in painful skin conditions and how Pain NRS and VAS were used in randomized clinical trials (RCTs) of painful skin conditions and rheumatoid arthritis. The results showed a discrepancy in how pain NRS/VAS were measured in the trials. In addition, the mean difference was the most common method of reporting pain.
Plain language summary available online</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35962565</pmid><doi>10.1111/bjd.21821</doi><tpages>854</tpages><orcidid>https://orcid.org/0000-0002-5257-1142</orcidid><orcidid>https://orcid.org/0000-0002-0298-7115</orcidid><orcidid>https://orcid.org/0000-0003-0534-2854</orcidid><orcidid>https://orcid.org/0000-0002-3265-4530</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2022-12, Vol.187 (6), p.846-854 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10087046 |
| source | Oxford University Press Journals All Titles (1996-Current); Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Clinical trials Collaboration Evidence‐Based Dermatology Hidradenitis Suppurativa - complications Hidradenitis Suppurativa - diagnosis Hidradenitis Suppurativa - therapy Humans Meta-analysis Pain Pain - diagnosis Pain - etiology Pain Measurement Patients Randomized Controlled Trials as Topic Rheumatoid arthritis Skin diseases Systematic Review |
| title | Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T00%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pain%20measurement%20in%20painful%20skin%20conditions%20and%20rheumatoid%20arthritis%20randomized%20controlled%20trials:%20a%20scoping%20review%20to%20inform%20pain%20measurement%20in%20hidradenitis%20suppurativa&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Hasan,%20Samar%20B.&rft.date=2022-12&rft.volume=187&rft.issue=6&rft.spage=846&rft.epage=854&rft.pages=846-854&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.21821&rft_dat=%3Cproquest_pubme%3E2745695663%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2745695663&rft_id=info:pmid/35962565&rfr_iscdi=true |